Allogene Therapeutics, Inc. (ALLO, Financial) saw a significant drop in its stock price, falling 5.06% to $2.54 per share. The trading volume reached 1.41 million shares, with a turnover rate of 0.67% and a volatility of 4.49%.
Recent financial reports show that the company recorded no revenue, a net loss of $66.36 million, an earnings per share (EPS) of -$0.35, and a gross loss of $3.64 million, resulting in a price-to-earnings (P/E) ratio of -1.60. Among the 18 institutions covering the stock, 72% recommended buying, 28% suggested holding, and none advised selling.
In the broader biotechnology sector, which experienced a decline of 0.96%, related stocks showed varied performances. Tc Biopharm (Holdings) Plc, Briacell Therapeutics Corp., and Bioatla, Inc. recorded notable gains, while Aditxt, Inc., Windtree Therapeutics, Inc., and Tc Biopharm (Holdings) Plc were highly active with significant turnover rates of 1284.26%, 71.69%, and 58.22%, respectively. Stocks with high volatility included Pasithea Therapeutics Corp., Tevogen Bio Holdings Inc., and Apollomics Inc.
Allogene Therapeutics Inc is a clinical-stage biotechnology firm specializing in immuno-oncology. The company develops genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their approach uses healthy donor cells, which broadens patient eligibility and scalability. Key projects target lymphoma, leukemia, autoimmune diseases, and solid tumors, with revenue primarily from partnerships and licensing agreements.
